Woburn biotech company ArQule Inc. has licensed a compound called ARQ 092 to Japanese firm Daiichi Sankyo Co. Ltd. to develop possible cancer treatments in a deal that could be worth up to $265 million to ArQule. Under terms of the deal, outlined in a filing with the U.S. Securities and Exchange Commission, ArQule (Nasdaq: ARQL) will get a $10 million up front payment from Daiichi, and could receive an additional $255 million in total from milestone payments as it reaches various stages in clinical development, regulatory approval and commercialization.
